Guanghui Hu

Guanghui Hu

Company: Naki Therapeutics

Job title: Chief Executive Officer


Developing CAR-NK Therapies for Solid Tumors 12:00 pm

We are developing a “combination” CAR-NK therapy (integrating IL15 with anti-CD147 CAR-NK) that has shown a great promise in treating solid tumors in pre-clinical studies We have also developed a NK / CAR-NK cell expansion technology platform with great expansion efficiency and fidelityRead more

day: Day 2: Pre-Clinical & Translational

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.